ORMP

Oramed Pharmaceuticals Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $117.95 million. The company's revenue for the trailing twelve months (TTM) is $2.00 million. The financial health of Oramed Pharmaceuticals Inc. is marked by significant losses, as indicated by an EBITDA of -$12,889,000 and a free cash flow of -$3,228,875. Despite this, the company has a substantial amount of cash on hand, totaling $134.69 million, with minimal debt of $860,000. The operating margin is -650.5%, while the profit margin is 2192.6%. The return on equity (ROE) is 24.5%, and the return on assets (ROA) is -4.2%. The valuation context for Oramed Pharmaceuticals Inc. is defined by a price-to-earnings ratio (P/E) of 2.90, a forward P/E of -37.00, and a price-to-book ratio of 0.59. The company's revenue growth rate is not available, nor are its earnings growth rates.